Cumberland Partners Ltd Has $1.08 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Cumberland Partners Ltd increased its holdings in United Therapeutics by 84.2%, bringing its total shares to 3,500 valued at approximately $1,079,000.
• United Therapeutics reported earnings of $6.41 per share for the last quarter, which fell short of consensus estimates by $0.39, with revenue reaching $798.6 million.
• Several hedge funds, including LPL Financial and Geode Capital Management, also significantly increased their stakes, contributing to institutional investors owning 94.08% of the company's stock.

Cumberland Partners Ltd grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 84.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,500 shares of the biotechnology company's stock after buying an additional 1,600 shares during the quarter. Cumberland Partners Ltd's holdings in United Therapeutics were worth $1,079,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. LPL Financial LLC lifted its holdings in United Therapeutics by 122.8% during the 4th quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock valued at $5,024,000 after purchasing an additional 7,847 shares during the last quarter. O Shaughnessy Asset Management LLC raised its stake in shares of United Therapeutics by 6.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 3,930 shares of the biotechnology company's stock valued at $1,387,000 after acquiring an additional 228 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of United Therapeutics by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after acquiring an additional 44,277 shares during the last quarter. Westpac Banking Corp grew its position in United Therapeutics by 6.5% during the 4th quarter. Westpac Banking Corp now owns 1,249 shares of the biotechnology company's stock worth $441,000 after acquiring an additional 76 shares during the last quarter. Finally, World Investment Advisors increased its holdings in United Therapeutics by 18.4% during the 4th quarter. World Investment Advisors now owns 1,299 shares of the biotechnology company's stock valued at $458,000 after purchasing an additional 202 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 70,681 shares of company stock valued at $21,318,359 over the last ninety days. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Stock Up 3.1%

United Therapeutics stock traded up $8.97 during mid-day trading on Tuesday, hitting $301.62. 53,702 shares of the company's stock were exchanged, compared to its average volume of 508,931. The company's 50 day simple moving average is $297.83 and its 200-day simple moving average is $312.42. The firm has a market capitalization of $13.61 billion, a P/E ratio of 11.76, a PEG ratio of 4.43 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's quarterly revenue was up 11.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.85 EPS. Research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of several research analyst reports. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price for the company. HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a "buy" rating in a research note on Thursday. Bank of America decreased their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Finally, Morgan Stanley cut their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $379.69.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.